TY - JOUR AU - Coates, L. C. AU - Kavanaugh, A. AU - Mease, P. J. AU - Soriano, E. R. AU - Laura Acosta-Felquer, M. AU - Armstrong, A. W. PY - 2016 DA - 2016// TI - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis JO - Arthritis Rheumatol VL - 68 ID - Coates2016 ER - TY - JOUR AU - FitzGerald, O. AU - Haroon, M. AU - Giles, J. T. AU - Winchester, R. PY - 2015 DA - 2015// TI - Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype JO - Arthritis Res Ther VL - 17 UR - https://doi.org/10.1186/s13075-015-0640-3 DO - 10.1186/s13075-015-0640-3 ID - FitzGerald2015 ER - TY - JOUR AU - Helliwell, P. S. AU - Kavanaugh, A. PY - 2014 DA - 2014// TI - Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab JO - Arthritis Care Res (Hoboken) VL - 66 UR - https://doi.org/10.1002/acr.22204 DO - 10.1002/acr.22204 ID - Helliwell2014 ER - TY - JOUR AU - Acosta Felquer, M. L. AU - Ferreyra Garrott, L. AU - Marin, J. AU - Catay, E. AU - Scolnik, M. AU - Scaglioni, V. PY - 2014 DA - 2014// TI - Remission criteria and activity indices in psoriatic arthritis JO - Clin Rheumatol VL - 33 UR - https://doi.org/10.1007/s10067-014-2626-y DO - 10.1007/s10067-014-2626-y ID - Acosta Felquer2014 ER - TY - JOUR AU - Sankoh, A. J. AU - Li, H. AU - D’Agostino, R. B. PY - 2014 DA - 2014// TI - Use of composite endpoints in clinical trials JO - Stat Med VL - 33 UR - https://doi.org/10.1002/sim.6205 DO - 10.1002/sim.6205 ID - Sankoh2014 ER - TY - JOUR AU - Schoels, M. PY - 2014 DA - 2014// TI - Psoriatic arthritis indices JO - Clin Exp Rheumatol VL - 32 ID - Schoels2014 ER - TY - JOUR AU - Orbai, A. M. AU - de Wit, M. AU - Mease, P. AU - Shea, J. A. AU - Gossec, L. AU - Leung, Y. Y. PY - 2017 DA - 2017// TI - International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2016-210242 DO - 10.1136/annrheumdis-2016-210242 ID - Orbai2017 ER - TY - JOUR AU - Meyer, D. M. AU - Jesson, M. I. AU - Li, X. AU - Elrick, M. M. AU - Funckes-Shippy, C. L. AU - Warner, J. D. PY - 2010 DA - 2010// TI - Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis JO - J Inflamm (Lond) VL - 7 UR - https://doi.org/10.1186/1476-9255-7-41 DO - 10.1186/1476-9255-7-41 ID - Meyer2010 ER - TY - JOUR AU - Mease, P. AU - Hall, S. AU - Fitzgerald, O. AU - van der Heijde, D. AU - Merola, J. F. AU - Avila-Zapata, F. PY - 2017 DA - 2017// TI - Tofacitinib or adalimumab versus placebo for psoriatic arthritis JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1615975 DO - 10.1056/NEJMoa1615975 ID - Mease2017 ER - TY - JOUR AU - Gladman, D. AU - Rigby, W. AU - Azevedo, V. F. AU - Behrens, F. AU - Blanco, R. AU - Kaszuba, A. PY - 2017 DA - 2017// TI - Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1615977 DO - 10.1056/NEJMoa1615977 ID - Gladman2017 ER - TY - JOUR AU - Helliwell, P. S. AU - FitzGerald, O. AU - Fransen, J. AU - Gladman, D. D. AU - Kreuger, G. G. AU - Callis-Duffin, K. PY - 2013 DA - 2013// TI - The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) JO - Ann Rheum Dis VL - 72 UR - https://doi.org/10.1136/annrheumdis-2012-201341 DO - 10.1136/annrheumdis-2012-201341 ID - Helliwell2013 ER - TY - JOUR AU - Mumtaz, A. AU - Gallagher, P. AU - Kirby, B. AU - Waxman, R. AU - Coates, L. C. AU - Veale, J. D. PY - 2011 DA - 2011// TI - Development of a preliminary composite disease activity index in psoriatic arthritis JO - Ann Rheum Dis VL - 70 UR - https://doi.org/10.1136/ard.2010.129379 DO - 10.1136/ard.2010.129379 ID - Mumtaz2011 ER - TY - JOUR AU - Madsen, O. R. PY - 2011 DA - 2011// TI - Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? JO - Clin Rheumatol VL - 30 UR - https://doi.org/10.1007/s10067-011-1847-6 DO - 10.1007/s10067-011-1847-6 ID - Madsen2011 ER - TY - JOUR AU - Husted, J. A. AU - Cook, R. J. AU - Farewell, V. T. AU - Gladman, D. D. PY - 2000 DA - 2000// TI - Methods for assessing responsiveness: a critical review and recommendations JO - J Clin Epidemiol VL - 53 UR - https://doi.org/10.1016/S0895-4356(99)00206-1 DO - 10.1016/S0895-4356(99)00206-1 ID - Husted2000 ER - TY - JOUR AU - Bhatti, I. P. AU - Lohano, H. D. AU - Pirzado, Z. A. AU - Jafri, I. A. PY - 2006 DA - 2006// TI - A logistic regression analysis of the ischemic heart disease risk JO - J Applied Sci VL - 6 UR - https://doi.org/10.3923/jas.2006.785.788 DO - 10.3923/jas.2006.785.788 ID - Bhatti2006 ER - TY - JOUR AU - Coates, L. C. AU - Fransen, J. AU - Helliwell, P. S. PY - 2010 DA - 2010// TI - Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2008.102053 DO - 10.1136/ard.2008.102053 ID - Coates2010 ER - TY - JOUR AU - Helliwell, P. S. AU - FitzGerald, O. AU - Fransen, J. PY - 2014 DA - 2014// TI - Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response JO - J Rheumatol VL - 41 UR - https://doi.org/10.3899/jrheum.140172 DO - 10.3899/jrheum.140172 ID - Helliwell2014 ER - TY - JOUR AU - Kavanaugh, A. AU - McInnes, I. B. AU - Mease, P. J. AU - Hall, S. AU - Chinoy, H. AU - Kivitz, A. J. PY - 2016 DA - 2016// TI - Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.160275 DO - 10.3899/jrheum.160275 ID - Kavanaugh2016 ER - TY - JOUR AU - Chatzidionysiou, K. AU - Kristensen, L. E. AU - Eriksson, J. AU - Askling, J. AU - van Vollenhoven, R. PY - 2015 DA - 2015// TI - Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register JO - Scand J Rheumatol VL - 44 UR - https://doi.org/10.3109/03009742.2015.1026840 DO - 10.3109/03009742.2015.1026840 ID - Chatzidionysiou2015 ER - TY - JOUR AU - Bykerk, V. P. AU - Ostor, A. J. AU - Alvaro-Gracia, J. AU - Pavelka, K. AU - Ivorra, J. A. AU - Graninger, W. PY - 2012 DA - 2012// TI - Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/annrheumdis-2011-201087 DO - 10.1136/annrheumdis-2011-201087 ID - Bykerk2012 ER - TY - JOUR AU - Coates, L. C. AU - Mahmood, F. AU - Emery, P. AU - Conaghan, P. G. AU - Helliwell, P. S. PY - 2017 DA - 2017// TI - The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2017-211137 DO - 10.1136/annrheumdis-2017-211137 ID - Coates2017 ER - TY - JOUR AU - Salaffi, F. AU - Ciapetti, A. AU - Carotti, M. AU - Gasparini, S. AU - Gutierrez, M. PY - 2014 DA - 2014// TI - Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world JO - Biomed Res Int VL - 2014 UR - https://doi.org/10.1155/2014/528105 DO - 10.1155/2014/528105 ID - Salaffi2014 ER - TY - JOUR AU - Coates, L. C. AU - Helliwell, P. S. PY - 2016 DA - 2016// TI - Defining low disease activity states in psoriatic arthritis using novel composite disease instruments JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.150826 DO - 10.3899/jrheum.150826 ID - Coates2016 ER - TY - JOUR AU - Chimenti, M. S. AU - Triggianese, P. AU - Conigliaro, P. AU - Tonelli, M. AU - Gigliucci, G. AU - Novelli, L. PY - 2017 DA - 2017// TI - A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors JO - Clin Rheumatol VL - 36 UR - https://doi.org/10.1007/s10067-017-3769-4 DO - 10.1007/s10067-017-3769-4 ID - Chimenti2017 ER - TY - JOUR AU - Schoels, M. M. AU - Aletaha, D. AU - Alasti, F. AU - Smolen, J. S. PY - 2016 DA - 2016// TI - Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-207507 DO - 10.1136/annrheumdis-2015-207507 ID - Schoels2016 ER - TY - STD TI - Acosta Felquer ML, Szentpetery A, Elmamoun M, Gallagher P, FitzGerald O, Soriano ER. Composite Psoriatic Disease Activity Index (CPDAI), defining remission and disease activity states using data from daily clinical practice [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). https://acrabstracts.org/abstract/composite-psoriatic-disease-activity-index-cpdai-defining-remission-and-disease-activity-states-using-data-from-daily-clinical-practice/. Accessed 16 Oct 2018. UR - https://acrabstracts.org/abstract/composite-psoriatic-disease-activity-index-cpdai-defining-remission-and-disease-activity-states-using-data-from-daily-clinical-practice/ ID - ref26 ER - TY - JOUR AU - Coates, L. C. AU - FitzGerald, O. AU - Gladman, D. D. AU - McHugh, N. AU - Mease, P. AU - Strand, V. PY - 2013 DA - 2013// TI - Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease JO - Arthritis Rheum VL - 65 UR - https://doi.org/10.1002/art.37939 DO - 10.1002/art.37939 ID - Coates2013 ER - TY - JOUR AU - Coates, L. C. AU - FitzGerald, O. AU - Merola, J. F. AU - Smolen, J. AU - van Mens, L. J. J. AU - Bertheussen, H. PY - 2018 DA - 2018// TI - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis JO - Arthritis Rheumatol VL - 70 UR - https://doi.org/10.1002/art.40391 DO - 10.1002/art.40391 ID - Coates2018 ER - TY - JOUR AU - Smolen, J. S. AU - Schöls, M. AU - Braun, J. AU - Dougados, M. AU - FitzGerald, O. AU - Gladman, D. D. PY - 2018 DA - 2018// TI - Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force JO - Ann Rheum Dis VL - 77 UR - https://doi.org/10.1136/annrheumdis-2017-211734 DO - 10.1136/annrheumdis-2017-211734 ID - Smolen2018 ER -